Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

Recent & Breaking News (OTCPK:ARLZQ)

Aralez to Acquire From AstraZeneca U.S. Rights to Beta Blocker Toprol-XL®

Canada NewsWire October 4, 2016

Aralez Announces U.S. Commercial Launch Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers

Canada NewsWire October 3, 2016

IIROC Trade Resumption - ARZ

Canada NewsWire September 15, 2016

Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers

Canada NewsWire September 15, 2016

IIROC Trading Halt - ARZ

Canada NewsWire September 15, 2016

IIROC Trade Resumption - Aralez Pharmaceuticals Inc.

Newsfile September 7, 2016

IIROC Trade Resumption - ARZ

Canada NewsWire September 7, 2016

IIROC Trade Halt - Aralez Pharmaceuticals Inc.

Newsfile September 7, 2016

IIROC Trading Halt - ARZ

Canada NewsWire September 7, 2016

Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck

Canada NewsWire September 7, 2016

Aralez Reports Second Quarter 2016 Financial Results

Canada NewsWire August 9, 2016

Aralez To Announce Second Quarter 2016 Results On August 9, 2016

Canada NewsWire July 26, 2016

Aralez To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference

Canada NewsWire July 6, 2016

Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics

PR Newswire June 23, 2016

Aralez Announces Voting Results From 2016 Annual General Meeting Of Shareholders

Canada NewsWire June 16, 2016

Aralez To Present At The Jefferies Healthcare Conference

Canada NewsWire June 2, 2016

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets

Marketwired June 1, 2016

Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma

PR Newswire May 20, 2016

Aralez Distributes Meeting Materials For 2016 Annual General Meeting Of Shareholders

Canada NewsWire May 16, 2016

Aralez Reports First Quarter 2016 Financial Results

Canada NewsWire May 10, 2016